Responders (patients with high tumor regression) showed a significantly lower MKI67 expression than nonresponders in the pretherapeutical tumor biopsies (81.2% versus 16.7%; p < 0.05) as well as in the posttherapeutical resection specimens (75.8% versus 14.3%; p < 0.01). This evidence concerns the gene MKI67 and neoplasm.